Company profile
Mera Pharmaceuticals, Inc.
OTC: MRPI · Healthcare · Biotechnology
#1166 of 1,422 Healthcare companies by revenuebottom-decile growth
EA Score
——FH —DQ —GM —SS 57
v0.1 · 5/100 weight · pillars only
↑ listing tenure, Piotroski F · ↓ revenue growth (YoY), 3-yr revenue growth
Methodology →Revenue TTM
$302.6k
Rev growth YoY (TTM)
+4.8%
Net income (FY)
-$6
Employees
74
as of 2026-08-28
Market cap
$55.7k
as of 2026-08-28
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$0$02020
Net income-$6-$62020
Operating income-$6-$62020
Total assets$0$02020
Liabilities$30$302020
Equity-$30-$302020
Revenue trend
FY2005 – FY2020 · USD
FY05
FY06
FY07
FY08
FY09
FY10
FY11
FY20
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Mera Pharmaceuticals, Inc.’s revenue?
Mera Pharmaceuticals, Inc. booked $0 in FY2020 revenue, contracting 100% year over year — among the slowest-growing Healthcare companies we track, at a -Infinity% net margin.
Peers · Healthcare
PaxMedica, Inc. Common Stock——Biome Grow Inc.——Street Capital Inc.18DHero Technologies Inc.——SOAFEE, Inc.——Nunzia Pharmaceutical Company——Neighbors
Clark →Key facts
CEOBenny Doro
SectorHealthcare
IndustryBiotechnology
HeadquartersLas Vegas, NV
ExchangeOTC: MRPI
Employees74
IPO date1995-02-01
Latest filings
No filings loaded — no CIK (non-SEC filer).
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.